<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://ict.sagepub.com">
<title>Integrative Cancer Therapies current issue</title>
<link>http://ict.sagepub.com</link>
<description>Integrative Cancer Therapies RSS feed -- current issue</description>
<prism:coverDisplayDate>September 2009</prism:coverDisplayDate>
<prism:publicationName>Integrative Cancer Therapies</prism:publicationName>
<prism:issn>1534-7354</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/reprint/8/3/203?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/reprint/8/3/205?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/8/3/208?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/8/3/228?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/8/3/235?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/8/3/242?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/8/3/254?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/8/3/261?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/8/3/273?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/8/3/280?rss=1" />
  <rdf:li rdf:resource="http://ict.sagepub.com/cgi/content/abstract/8/3/283?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://ict.sagepub.com:80/icons/banner/title.gif" />
</channel>

<image rdf:about="http://ict.sagepub.com:80/icons/banner/title.gif">
<title>Integrative Cancer Therapies</title>
<url>http://ict.sagepub.com:80/icons/banner/title.gif</url>
<link>http://ict.sagepub.com</link>
</image>

<item rdf:about="http://ict.sagepub.com/cgi/reprint/8/3/203?rss=1">
<title><![CDATA[In This Issue]]></title>
<link>http://ict.sagepub.com/cgi/reprint/8/3/203?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Block, K. I.]]></dc:creator>
<dc:date>Thu, 08 Oct 2009 04:26:33 PDT</dc:date>
<dc:identifier>info:doi/10.1177/1534735409345361</dc:identifier>
<dc:title><![CDATA[In This Issue]]></dc:title>
<prism:number>3</prism:number>
<prism:volume>8</prism:volume>
<prism:endingPage>204</prism:endingPage>
<prism:publicationDate>2009-09-01</prism:publicationDate>
<prism:startingPage>203</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/reprint/8/3/205?rss=1">
<title><![CDATA[Could Integrative Cancer Treatment be Cost-Saving and Resuscitate a Submerged Medical System?]]></title>
<link>http://ict.sagepub.com/cgi/reprint/8/3/205?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Block, K. I.]]></dc:creator>
<dc:date>Thu, 08 Oct 2009 04:26:33 PDT</dc:date>
<dc:identifier>info:doi/10.1177/1534735409344978</dc:identifier>
<dc:title><![CDATA[Could Integrative Cancer Treatment be Cost-Saving and Resuscitate a Submerged Medical System?]]></dc:title>
<prism:number>3</prism:number>
<prism:volume>8</prism:volume>
<prism:endingPage>207</prism:endingPage>
<prism:publicationDate>2009-09-01</prism:publicationDate>
<prism:startingPage>205</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/8/3/208?rss=1">
<title><![CDATA[Drug--Botanical Interactions: A Review of the Laboratory, Animal, and Human Data for 8 Common Botanicals]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/8/3/208?rss=1</link>
<description><![CDATA[<p>Many Americans use complementary and alternative medicine (CAM) to prevent or alleviate common illnesses, and these medicines are commonly used by individuals with cancer.These medicines or botanicals share the same metabolic and transport proteins, including cytochrome P450 enzymes (CYP), glucuronosyltransferases (UGTs), and P-glycoprotein (Pgp), with over-the-counter and prescription medicines increasing the likelihood of drug&mdash;botanical interactions.This review provides a brief description of the different proteins, such as CYPs, UGTs, and Pgp.The potential effects of drug&mdash;botanical interactions on the pharmacokinetics and pharmacodynamics of the drug or botanical and a summary of the more common models used to study drug metabolism are described.The remaining portion of this review summarizes the data extracted from several laboratory, animal, and clinical studies that describe the metabolism, transport, and potential interactions of 8 selected botanicals. The 8 botanicals include black cohosh, <I>Echinacea</I>, garlic, <I> Gingko biloba</I>, green tea, kava, milk thistle, and St John&rsquo;s wort; these botanicals are among some of the more common botanicals taken by individuals with cancer.These examples are included to demonstrate how to interpret the different studies and how to use these data to predict the likelihood of a clinically significant drug&mdash;botanical interaction.</p>]]></description>
<dc:creator><![CDATA[Shord, S. S., Shah, K., Lukose, A.]]></dc:creator>
<dc:date>Thu, 08 Oct 2009 04:26:33 PDT</dc:date>
<dc:identifier>info:doi/10.1177/1534735409340900</dc:identifier>
<dc:title><![CDATA[Drug--Botanical Interactions: A Review of the Laboratory, Animal, and Human Data for 8 Common Botanicals]]></dc:title>
<prism:number>3</prism:number>
<prism:volume>8</prism:volume>
<prism:endingPage>227</prism:endingPage>
<prism:publicationDate>2009-09-01</prism:publicationDate>
<prism:startingPage>208</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/8/3/228?rss=1">
<title><![CDATA[A Randomized Controlled Trial of the Effects of Transcendental Meditation on Quality of Life in Older Breast Cancer Patients]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/8/3/228?rss=1</link>
<description><![CDATA[<p>This single-blind, randomized controlled trial evaluated the impact of the Transcendental Meditation program plus standard care as compared with standard care alone on the quality of life (QOL) of older women (&ge;55 years) with stage II to IV breast cancer. One hundred and thirty women (mean age = 63.8) were randomly assigned to either experimental (n = 64) or control (n = 66) groups. Functional Assessment of Cancer Therapy&mdash;Breast (FACT-B), Functional Assessment of Chronic Illness Therapy&mdash; Spiritual Well-Being (FACIT-SP), and Short-Form (SF)-36 mental health and vitality scales were administered every 6 months over an average 18-month intervention period. Significant improvements were found in the Transcendental Meditation group compared with controls in overall QOL, measured by the FACT-B total score (<I>P</I> = .037), emotional well-being (<I>P</I> = .046), and social well-being (<I>P</I> = .003) subscales, and SF-36 mental health (<I> P</I> = .017). Results indicate that the Transcendental Meditation technique improves the QOL of older breast cancer patients. It is recommended that this stress reduction program, with its ease of implementation and home practice, be adopted in public health programs.</p>]]></description>
<dc:creator><![CDATA[Nidich, S. I., Fields, J. Z., Rainforth, M. V., Pomerantz, R., Cella, D., Kristeller, J., Salerno, J. W., Schneider, R. H.]]></dc:creator>
<dc:date>Thu, 08 Oct 2009 04:26:33 PDT</dc:date>
<dc:identifier>info:doi/10.1177/1534735409343000</dc:identifier>
<dc:title><![CDATA[A Randomized Controlled Trial of the Effects of Transcendental Meditation on Quality of Life in Older Breast Cancer Patients]]></dc:title>
<prism:number>3</prism:number>
<prism:volume>8</prism:volume>
<prism:endingPage>234</prism:endingPage>
<prism:publicationDate>2009-09-01</prism:publicationDate>
<prism:startingPage>228</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/8/3/235?rss=1">
<title><![CDATA[Integrative Tumor Board: A Case Report and Discussion From Dana-Farber Cancer Institute]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/8/3/235?rss=1</link>
<description><![CDATA[<p>A 34-year-old woman carrying a BRCA1 gene and a significant family history was diagnosed with T1c, N1 breast cancer. The tumor was estrogen receptor, progesterone receptor, and HER-2/Neu negative.The patient received dose-dense chemotherapy with Adriamycin and Cytoxan followed by Taxol, and left breast irradiation. Later, a bilateral S-GAP flap reconstruction with right prophylactic mastectomy and left mastectomy were performed. During her treatment, the patient had an integrative medicine consultation and was seen by a team of health care providers specializing in integrative therapies, including integrative nutrition, therapeutic massage, acupuncture, and yoga. Each modality contributed unique benefit in her care that led to a satisfactory outcome for the patient.A detailed discussion regarding her care from each modality is presented.The case elucidates the need for integrative approaches for cancer patients in a conventional medical setting.</p>]]></description>
<dc:creator><![CDATA[Lu, W., Ott, M. J., Kennedy, S., Mathay, M. B., Doherty-Gilman, A. M., Dean-Clower, E., Hayes, C. M., Rosenthal, D. S.]]></dc:creator>
<dc:date>Thu, 08 Oct 2009 04:26:33 PDT</dc:date>
<dc:identifier>info:doi/10.1177/1534735409343446</dc:identifier>
<dc:title><![CDATA[Integrative Tumor Board: A Case Report and Discussion From Dana-Farber Cancer Institute]]></dc:title>
<prism:number>3</prism:number>
<prism:volume>8</prism:volume>
<prism:endingPage>241</prism:endingPage>
<prism:publicationDate>2009-09-01</prism:publicationDate>
<prism:startingPage>235</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/8/3/242?rss=1">
<title><![CDATA[Pomegranate Fruit Extract Impairs Invasion and Motility in Human Breast Cancer]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/8/3/242?rss=1</link>
<description><![CDATA[<p><I>Purpose.</I> Pomegranate fruit extracts (PFEs) possess polyphenolic and other compounds with antiproliferative, pro-apoptotic and anti-inflammatory effects in prostate, lung, and other cancers. Because nuclear transcription factor-kB (NF-kB) is known to regulate cell survival, proliferation, tumorigenesis, and inflammation, it was postulated that PFEs may exert anticancer effects at least in part by modulating NF-kB activity. <I>Experimental design.</I> The authors investigated the effect of a novel, defined PFE consisting of both fermented juice and seed oil on the NF-kB pathway, which is constitutively active in aggressive breast cancer cell lines. The effects of the PFE on NF-kB&mdash;regulated cellular processes such as cell survival, proliferation, and invasion were also examined. <I> Results.</I> Analytical characterization of the bioactive components of the PFE revealed active constituents, mainly ellagitannins and phenolic acids in the aqueous PFE and conjugated octadecatrienoic acids in the lipid PFE derived from seeds.The aqueous PFE dose-dependently inhibited NF-kB&mdash;dependent reporter gene expression associated with proliferation, invasion, and motility in aggressive breast cancer phenotypes while decreasing RhoC and RhoA protein expression. <I>Conclusion.</I> Inhibition of motility and invasion by PFEs, coincident with suppressed RhoC and RhoA protein expression, suggests a role for these defined extracts in lowering the metastatic potential of aggressive breast cancer species.</p>]]></description>
<dc:creator><![CDATA[Khan, G. N., Gorin, M. A., Rosenthal, D., Pan, Q., Bao, L. W., Wu, Z. F., Newman, R. A., Pawlus, A. D., Yang, P., Lansky, E. P., Merajver, S. D.]]></dc:creator>
<dc:date>Thu, 08 Oct 2009 04:26:33 PDT</dc:date>
<dc:identifier>info:doi/10.1177/1534735409341405</dc:identifier>
<dc:title><![CDATA[Pomegranate Fruit Extract Impairs Invasion and Motility in Human Breast Cancer]]></dc:title>
<prism:number>3</prism:number>
<prism:volume>8</prism:volume>
<prism:endingPage>253</prism:endingPage>
<prism:publicationDate>2009-09-01</prism:publicationDate>
<prism:startingPage>242</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/8/3/254?rss=1">
<title><![CDATA[Inhibition of Viral Carcinogenesis by Phyllanthus amarus]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/8/3/254?rss=1</link>
<description><![CDATA[<p>Friend murine leukemia virus (FMuLv) is an acutely oncogenic retrovirus, and its infection leads to erythroblastosis and leukemia in mice. This infection model is used in the search for new antiviral agents. In the present study, the authors have evaluated the potential of an extract of <I>Phyllanthus amarus</I> against FMuLv-induced erythroleukemia in BALB/c mice. Injection of newborn mice with FMuLv resulted in leukemia and animals died due to splenomegaly. Oral administration of <I>P.amarus</I> was found to enhance the life span of leukemia-harboring animals and decrease the incidence of anemia. The authors also performed a series of hematological, biochemical, histopathological, and gene expression analyses to evaluate the effect of <I>P.amarus</I> administration on erythroleukemia initiation and progression. The data obtained indicate that <I>P.amarus</I> administration could significantly decrease the progression of erythroleukemia. Treatment with <I>P.amarus</I> induced the expression of p53 and p45NFE2 and decreased the expression of Bcl-2 in the spleen of infected mice. Histopathological evaluations of the spleen demonstrated that administration of <I>P.amarus</I> decreased the infiltration of leukemic cells into the sinusoidal space when compared with the vehicle treated group. <I>P.amarus</I> is known to inhibit chemically induced neoplasm in different rodent models.The current results indicate that <I>P.amarus</I> has the ability to suppress virally induced cancers as well.</p>]]></description>
<dc:creator><![CDATA[Harikumar, K. B., Kuttan, G., Kuttan, R.]]></dc:creator>
<dc:date>Thu, 08 Oct 2009 04:26:33 PDT</dc:date>
<dc:identifier>info:doi/10.1177/1534735409340162</dc:identifier>
<dc:title><![CDATA[Inhibition of Viral Carcinogenesis by Phyllanthus amarus]]></dc:title>
<prism:number>3</prism:number>
<prism:volume>8</prism:volume>
<prism:endingPage>260</prism:endingPage>
<prism:publicationDate>2009-09-01</prism:publicationDate>
<prism:startingPage>254</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/8/3/261?rss=1">
<title><![CDATA[Podophyllum hexandrum Fraction (REC-2006) Shows Higher Radioprotective Efficacy in the p53-Carrying Hepatoma Cell Line: A Role of Cell Cycle Regulatory Proteins]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/8/3/261?rss=1</link>
<description><![CDATA[<p>The present study was carried out to evaluate the radioprotective efficacy of <I>Podophyllum hexandrum</I> fraction (REC-2006) in hepatoma cell lines having different p53 statuses. Higher radioresistance was observed in the HepG2 (p53<sup>++</sup>) cell line in comparison to the Hep3B (p53<sup>--</sup>) cell line, indicating a plausible role of p53 in radioresistance. REC-2006 exhibited nearly twice the survival in p53-expressing HepG2 cells compared with p53-negative Hep3B cells. REC-2006 treatment alone induced p53 expression as compared with untreated controls. However, REC-2006 reduced p53 expression when treated 2 hours before irradiation as compared with the irradiated HepG2 controls, indicating that REC-2006 modulates the expression of p53 to mitigate its apoptotic effect. Induction of p21 in the REC-2006 + radiation treatment group downregulated the expression of cyclin E and CDK2, leading to a delay in the G1 phase of HepG2 cells, which provided time for DNA repair or related processes. However, no significant difference in CDC2 expression in both cell lines suggested that G2 phase arrest might not be the only responsible factor for REC-2006-mediated radioprotection. Significant induction of PCNA and GADD45 expression in HepG2 cells suggested that REC-2006 increased the percentage survival of HepG2 cells by increasing the span of time as well as efficacy for repair processes. In conclusion, REC-2006 modulated the expression of p53 and thereby promoted cell cycle arrest in the G1 phase, encouraging cell proliferation and DNA repair and thus providing significantly higher protection against acute -radiation in the HepG2 cell line.</p>]]></description>
<dc:creator><![CDATA[Singh, P. K., Kumar, R., Sharma, A., Arora, R., Chawla, R., Jain, S. K., Sharma, R. K.]]></dc:creator>
<dc:date>Thu, 08 Oct 2009 04:26:33 PDT</dc:date>
<dc:identifier>info:doi/10.1177/1534735409343589</dc:identifier>
<dc:title><![CDATA[Podophyllum hexandrum Fraction (REC-2006) Shows Higher Radioprotective Efficacy in the p53-Carrying Hepatoma Cell Line: A Role of Cell Cycle Regulatory Proteins]]></dc:title>
<prism:number>3</prism:number>
<prism:volume>8</prism:volume>
<prism:endingPage>272</prism:endingPage>
<prism:publicationDate>2009-09-01</prism:publicationDate>
<prism:startingPage>261</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/8/3/273?rss=1">
<title><![CDATA[Anticancer Activity of an Indian Medicinal Plant, Alstonia scholaris, on Skin Carcinogenesis in Mice]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/8/3/273?rss=1</link>
<description><![CDATA[<p>Alstonia scholaris, commonly known as sapthaparna, has been used for centuries in Ayurvedic medicine for treatment of various disorders. The objective of this study was to investigate the possible chemopreventive and anti-oxidative properties of this medicinal plant on two-stage process of skin carcinogenesis induced by a single application of 7, 12-dimethyabenz(a)anthrecene (100 lg/100 ll acetone), and two weeks later, promoted by repeated application of croton oil (1% in acetone/thrice a week) till the end of the experiment (16 weeks) in Swiss albino mice.The tumor incidence, tumor yield, tumor burden and cumulative number of papillomas were found to be higher in the carcinogen treated control (without ASE treatment) as compared to experimental animals (ASE treated). Furthermore, a significant increase in reduced glutathione, superoxide dismutase and catalase but decrease in lipid peroxidation was measured in ASE administered experimental groups than the carcinogen treated control. The present study demonstrates the chemopreventive potential of Alstonia scholaris bark extract in DMBA-induced skin tumorigenesis in Swiss albino mice.</p>]]></description>
<dc:creator><![CDATA[Jahan, S., Chaudhary, R., Goyal, P. K.]]></dc:creator>
<dc:date>Thu, 08 Oct 2009 04:26:33 PDT</dc:date>
<dc:identifier>info:doi/10.1177/1534735409343590</dc:identifier>
<dc:title><![CDATA[Anticancer Activity of an Indian Medicinal Plant, Alstonia scholaris, on Skin Carcinogenesis in Mice]]></dc:title>
<prism:number>3</prism:number>
<prism:volume>8</prism:volume>
<prism:endingPage>279</prism:endingPage>
<prism:publicationDate>2009-09-01</prism:publicationDate>
<prism:startingPage>273</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/8/3/280?rss=1">
<title><![CDATA[Gamma Knife--Treated Hepatoma: Case of Obstructive Jaundice and Management]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/8/3/280?rss=1</link>
<description><![CDATA[<p>Gamma knife therapy is becoming more frequently applied in solid tumor treatment. This article reports a unique case of severe obstructive jaundice arising as a complication of treatment of hepatoma at the hepatic hilum using a gamma knife.While planning an intervention, some images seem to promise success but actually lead to failure. Radiation damage to specific organs is difficult to predict because of several variables. Radiation-induced fibrosis and necrosis are the most common long-term adverse effects of radiotherapy; they are usually considered irreversible and result in induration and firmness of the tissue.To minimize radiation fibrosis, accurate patient positioning and tumor relocalization are essential for gamma knife use in the liver and other extracranial sites. Even when practiced frequently, any intervention must be delivered with caution if the liver has been treated with radiation. Otherwise, even with much experience, the unwary doctor can be trapped by deceptive images.</p>]]></description>
<dc:creator><![CDATA[Wang, M.-Q., Zou, Q., He, Q., Guan, Y.-S.]]></dc:creator>
<dc:date>Thu, 08 Oct 2009 04:26:33 PDT</dc:date>
<dc:identifier>info:doi/10.1177/1534735409343445</dc:identifier>
<dc:title><![CDATA[Gamma Knife--Treated Hepatoma: Case of Obstructive Jaundice and Management]]></dc:title>
<prism:number>3</prism:number>
<prism:volume>8</prism:volume>
<prism:endingPage>282</prism:endingPage>
<prism:publicationDate>2009-09-01</prism:publicationDate>
<prism:startingPage>280</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://ict.sagepub.com/cgi/content/abstract/8/3/283?rss=1">
<title><![CDATA[Sonodynamic and Photodynamic Therapy in Advanced Breast Carcinoma: A Report of 3 Cases]]></title>
<link>http://ict.sagepub.com/cgi/content/abstract/8/3/283?rss=1</link>
<description><![CDATA[<p>Photodynamic therapy (PDT) is an established therapeutic method, first approved by the FDA for certain kinds of cancer in 1998. There are also increasing data to show that a related procedure, sonodynamic therapy (SDT), is a promising new modality for cancer treatment. Here, the authors report clinical results in 3 advanced refractory breast cancer patients who were treated using a combination of sonodynamic and photodynamic therapy (SPDT), along with conventional therapies. All 3 patients had pathologically proven metastatic breast carcinoma. These widely disseminated carcinomas had ultimately failed to respond to conventional therapy. A new sensitizing agent, Sonoflora 1<SUP><SMALL><SMALL>TM</SMALL></SMALL></SUP> (SF1) was administered sublingually; then, after a 24-hour delay, patients were treated with a combination of light and ultrasound. All patients had significant partial or complete responses. SPDT is a promising new therapeutic combination for the treatment of breast cancer.</p>]]></description>
<dc:creator><![CDATA[Wang, X., Zhang, W., Xu, Z., Luo, Y., Mitchell, D., Moss, R. W.]]></dc:creator>
<dc:date>Thu, 08 Oct 2009 04:26:33 PDT</dc:date>
<dc:identifier>info:doi/10.1177/1534735409343693</dc:identifier>
<dc:title><![CDATA[Sonodynamic and Photodynamic Therapy in Advanced Breast Carcinoma: A Report of 3 Cases]]></dc:title>
<prism:number>3</prism:number>
<prism:volume>8</prism:volume>
<prism:endingPage>287</prism:endingPage>
<prism:publicationDate>2009-09-01</prism:publicationDate>
<prism:startingPage>283</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

</rdf:RDF>